Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-208 in metastatic castration-resistant prostate cancer
2024-517439-39-00Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Orion Corporation. Primary endpoints: Safety and tolerability, Maximum tolerated dose and dose-limiting toxicities and 1 more. Started Oct 2024; status: completed.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-517439-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517439-39-00.